miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1

World J Gastroenterol. 2017 Dec 14;23(46):8140-8151. doi: 10.3748/wjg.v23.i46.8140.

Abstract

Aim: To evaluate the levels of miR-192-5p in non-alcoholic fatty liver disease (NAFLD) models and demonstrate the role of miR-192-5p in lipid accumulation.

Methods: Thirty Sprague Dawley rats were randomly divided into three groups, which were given a standard diet, a high-fat diet (HFD), and an HFD with injection of liraglutide. At the end of 16 weeks, hepatic miR-192-5p and stearoyl-CoA desaturase 1 (SCD-1) levels were measured. MiR-192-5p mimic and inhibitor and SCD-1 siRNA were transfected into Huh7 cells exposed to palmitic acid (PA). Lipid accumulation was evaluated by oil red O staining and triglyceride assays. Direct interaction was validated by dual-luciferase reporter gene assays.

Results: The HFD rats showed a 0.46-fold decrease and a 3.5-fold increase in hepatic miR-192-5p and SCD-1 protein levels compared with controls, respectively, which could be reversed after disease remission by liraglutide injection (P < 0.01). The Huh7 cells exposed to PA also showed down-regulation and up-regulation of miR-192-5p and SCD-1 protein levels, respectively (P < 0.01). Transfection with miR-192-5p mimic and inhibitor in Huh7 cells induced dramatic repression and promotion of SCD-1 protein levels, respectively (P < 0.01). Luciferase activity was suppressed and enhanced by miR-192-5p mimic and inhibitor, respectively, in wild-type SCD-1 (P < 0.01) but not in mutant SCD-1. MiR-192-5p overexpression reduced lipid accumulation significantly in PA-treated Huh7 cells, and SCD-1 siRNA transfection abrogated the lipid deposition aggravated by miR-192-5p inhibitor (P < 0.01).

Conclusion: This study demonstrates that miR-192-5p has a negative regulatory role in lipid synthesis, which is mediated through its direct regulation of SCD-1.

Keywords: High fat diet; Lipid synthesis; Non-alcoholic fatty liver disease; Stearoyl-CoA desaturase 1; miR-192-5p.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Diet, High-Fat / adverse effects
  • Disease Models, Animal
  • Down-Regulation
  • Gene Knockdown Techniques
  • Humans
  • Lipogenesis / drug effects
  • Lipogenesis / genetics*
  • Liraglutide / therapeutic use
  • Liver / pathology*
  • Male
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Non-alcoholic Fatty Liver Disease / drug therapy
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / genetics
  • Non-alcoholic Fatty Liver Disease / pathology*
  • Palmitic Acid / pharmacology
  • RNA, Small Interfering / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Stearoyl-CoA Desaturase / genetics*
  • Stearoyl-CoA Desaturase / metabolism
  • Up-Regulation

Substances

  • MIRN192 microRNA, rat
  • MicroRNAs
  • RNA, Small Interfering
  • Palmitic Acid
  • Liraglutide
  • Stearoyl-CoA Desaturase
  • stearoyl-CoA desaturase SCD-1, rat